MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1021/acs.molpharmaceut.6c00454

Медицинская библиотека · Molecular pharmaceutics · 2026

Preclinical Evaluation of B7-H3-Targeted ADC-Based Molecular Imaging in Lung and Triple-Negative Breast Cancer.

Sui Jiayu, Qin Jingjie, Hsu Jessica C, Saladin Rachel J, Barnhart Todd E, Engle Jonathan W, Hu Xudong, Yu Jinming, Cai Weibo, Wei Yuchun

СтатьяПеревод пока не подготовлен

Аннотация

B7-H3 is widely expressed in multiple solid tumors but shows minimal expression in normal tissues, making it an ideal target for molecular imaging; however, its systematic investigation remains limited. In this study, we utilized the clinically investigated B7-H3-targeted antibody-drug conjugate (ADC) HS-20093 to develop and evaluate a novel immuno-positron emission tomography (immuno-PET) tracer, [89Zr]Zr-DFO-HS-20093, for accurate imaging of B7-H3 expression in lung cancer and triple-negative breast cancer models. [89Zr]Zr-DFO-HS-20093 was synthesized with high radiochemical purity (98.2 ± 0.6%). Cellular uptake assays revealed significantly higher tracer uptake in A549 cells than in 4T1 cells at 1, 2, and 4 h (all P < 0.0001), which was markedly reduced by blocking with excess unlabeled antibody. Immunofluorescence revealed predominant membrane localization of B7-H3 in 4T1 cells, whereas A549 cells exhibited pronounced intracellular distribution, suggesting enhanced internalization. In tumor-bearing mice, [89Zr]Zr-DFO-HS-20093 positron emission tomography (PET)/CT enabled clear tumor visualization, with peak uptake at 24 h post-injection in both A549 and 4T1 xenografts (9.63 ± 1.97 and 7.15 ± 3.14 μCi/mL, respectively), supporting its potential for tumor imaging. Ex vivo biodistribution data corroborated the PET findings, showing significantly higher tracer uptake in A549 tumors (5.01 ± 1.19 % ID/g) than in blocked tumors (2.89 ± 0.43 % ID/g) and 4T1 tumors (1.89 ± 0.47 % ID/g) (P = 0.034 and P = 0.003, respectively). Immunohistochemical analysis of A549 xenografts showed strong B7-H3 expression (3+), whereas 4T1 tumors exhibited lower expression levels (1-2+), further confirming that B7-H3 expression patterns were consistent with the imaging results. [89Zr]Zr-DFO-HS-20093 enables sensitive immuno-PET imaging of B7-H3 and reveals tumor-type-dependent differences in B7-H3 expression and intracellular behavior.

Для цитирования: Sui Jiayu, Qin Jingjie, Hsu Jessica C, Saladin Rachel J, Barnhart Todd E, Engle Jonathan W, Hu Xudong, Yu Jinming, Cai Weibo, Wei Yuchun. Preclinical Evaluation of B7-H3-Targeted ADC-Based Molecular Imaging in Lung and Triple-Negative Breast Cancer.. Molecular pharmaceutics. 2026. DOI: 10.1021/acs.molpharmaceut.6c00454.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.